We caught up with Professors Peter Schmid and Gary Middleton of the TORCMEK study team about the challenges and successes of their ongoing trial.
Q. What is the anticipated patient benefit of the TORCMEK trial?
TORCMEK aims to establish the feasible dose, regimen and efficacy of the mTOR inhibitor AZD2014 and the MEK inhibitor selumetinib when given in combination.
Breast cancer patients who have radiotherapy targeted at the original tumour site experience fewer side effects five years after treatment than those who have whole breast radiotherapy, and their cancer is just as unlikely to return, according to trial results published in The Lancet recently. The Cancer Research UK-funded IMPORT LOW trial revealed that five years after treatment, almost all patients were disease free.
The Programme Office has successfully recruited to four new roles: Student Combinations Alliance Assistant, Project Officer, Project Manager (Workforce) and Project Manager (Network Capabilities).
Eleanor (Ellie) Foot is the new Project Officer. Ellie joined the Programme Office at the end of July and will be supporting the team with upcoming projects.
Hannah Brown has been promoted to Project Manager (Workforce), where she will oversee the Nurses and Junior Investigator network groups alongside the PPI advisory group.
The Centre for Drug Development is pleased to announce the successful conclusion of its tender for biomarker delivery for early phase clinical trial work.
The tender included both novel assay development and sample processing. The tender was the first of its kind to be issued to the ECMC network. Positive responses from across the network at the expression of interest stage indicated a strong willingness to consider a new way of working within academia.
Following on from the success of the first workshop in London earlier this year, CRUK’s Centre for Drug Development (CDD), in collaboration with the ECMC Programme Office, hosted a second workshop, ‘Delivery of Early Phase Trials: How can we excel?’, in Newcastle on 22 June 2017.
Pre-announcement: Newcastle University is seeking to recruit a new Clinical Chair in Molecular Pathology. This exciting opportunity will be advertised in September 2017. We will be looking for a talented and highly motivated individual to spearhead our programme in Molecular Pathology, working closely with the Newcastle EPSRC/MRC Molecular Pathology Node (www.newcastlepathnode.org.uk) one of six awarded across the UK.
From September 2017, the ECMC Patient and Public Involvement Group will be offering a new advisory service to the ECMC network. If your ECMC does not currently have capacity to undertake an involvement activity in a project, you can come to the ECMC PPI Group for input. This could include:
As part of the new quinquennium, Cardiff ECMC has begun setting up an ECMC Haematology network.
The main purpose of the network is to promote haematology activities within the ECMC, and consider ways in which a collective group can:
· Attract more early-phase haematology trials within the ECMC and share information about them
· Initiate academic early-phase trials (ideas and proposals, joining up infrastructure etc)